Ovarian%20mass Treatment

Treatment

Pharmacotherapy

Combination Oral Contraceptives (OCs)

Combination OCs do not provide an advantage in the treatment of functional ovarian cysts when compared with expectant management
- Studies suggested that expectant management is as effective as hormonal treatment for the resolution of functional ovarian cysts
Patients may be offered OCs if they are seeking contraception
Estrogen/progestogen therapy may be useful in patients with anovulatory cycles who need OCs to induce the next period
Many combination OCs are available. Please see the latest MIMS for specific prescribing information

Management of recurrent implantation failure during the COVID-19 pandemic

Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022

Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.

Product Highlight - Evenity

01 Dec 2021

Romosozumab 105 mg/1.17 mL soln for inj